UPDATE: Bank of America Initiates Coverage on Enzymotec Ltd. on Good Position in Attractive Industry

In a report published Tuesday, Bank of America analyst Bryan D. Spillane initiated coverage on Enzymotec Ltd. ENZY with a Buy rating and $21.00 price target. In the report, Bank of America noted, “We are initiating coverage of Enzymotec (ENZY) with a Buy rating and $21 PO. In our view, ENZY offers investors attractive growth potential due its exposure to the large and growing consumer health and wellness end markets. Its positioning as a nutritional ingredients and medical foods company with clinically-validated products places the company on the frontier of functional foods where consumers are searching for solutions to medical concerns and preventative care.” Enzymotec Ltd. closed on Monday at $17.81.